Market Overview

Delta Oil & Gas Appoints Jordan P. Balencic, D.O. as Chief Compliance Officer


Delta Oil & Gas, Inc. (the "Company") (OTCQB:DLTA), is pleased to
announce the appointment of Dr. Jordan P. Balencic as Chief Compliance
Officer, effective immediately. Dr. Balencic, age 31, is a physician
entrepreneur currently serving the U.S. Department of Veterans Affairs
who has over 10 years of experience in market strategy, equity
investments, mergers and acquisitions, public company compliance and
turnarounds. This appointment was completed to support the Company in
the execution of its business plan by initially launching a turnaround
strategy to include completing the Company's audits, state filings and
SEC filings to regain compliance as a fully reporting OTCQB Company.

Dr. Balencic's initial focus will be to support management in becoming
fully compliant again while executing planned acquisitions already being
evaluated and negotiated to begin expansion of the Company's currently
producing portfolio.

"I am honored to join Delta to help re-energize its portfolio, regain
compliance status, and position for an aggressive merger & acquisition
program. Considering record U.S. oil production, record demand and oil
prices touching 4-year highs, the sector appears to be ready for
consolidation. Strategic buyers like Delta are considering deals to
achieve scale, fill in portfolios or enhance capabilities. After I
reviewed the list of potential acquisitions for Delta, this became an
opportunity that deeply piqued my interest. The impressive potential of
these acquisitions is what encouraged me to join the Delta team," stated
Chief Compliance Officer Dr. Balencic.

About Delta Oil & Gas, Inc.

Delta Oil & Gas, Inc. (OTCQB:DLTA) is an energy holding company which
targets projects or businesses that are of extremely high quality, low
to medium risk, and close to hydrocarbon delivery points. The Company
operates exclusively within North America. We currently hold substantial
land positions with varying working Interests in a number of California
regional plays, Texas and Oklahoma - with a focus on larger and much
higher impact targets in the USA of both conventional oil and gas

About Jordan P. Balencic, D.O.

Dr. Balencic is a physician entrepreneur with a passion for using his
clinical knowledge and business acumen to improve human health. He is
Chief Executive Officer of ERApeutics™ (;
a physician-led health company focused on the development of
evidence-based dietary supplements, nutraceuticals and medical foods
that support brain health and improve the way people age. Dr. Balencic
is the creator of Prolimbic 29™, a clinically-studied brain health
supplement currently gaining traction in the marketplace. He has
extensive product development, consulting and healthcare advisory
experience for both private and public companies. Dr. Balencic also
serves as Chairman of the Board of Directors of True Nature Holding,
Inc. (OTCQB:TNTY), a turn-around public company applying technology to
improve healthcare for both humans and pets. Dr. Balencic completed his
Internal Medicine Residency training at Pennsylvania State University,
obtained his Medical Doctoral degree at Lake Erie College of Osteopathic
Medicine, and has a Bachelor of Science in Biology from Gannon

OTC Markets Profile:

Full FCC Disclosure and Disclaimer:

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at